Literature DB >> 32612264

Rebalancing protein synthesis in fragile X syndrome.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32612264     DOI： 10.1038/d41573-020-00100-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome.

Authors:  Patrick K McCamphill; Laura J Stoppel; Rebecca K Senter; Michael C Lewis; Arnold J Heynen; David C Stoppel; Vinay Sridhar; Katie A Collins; Xi Shi; Jen Q Pan; Jon Madison; Jeffrey R Cottrell; Kimberly M Huber; Edward M Scolnick; Edward B Holson; Florence F Wagner; Mark F Bear
Journal:  Sci Transl Med       Date:  2020-05-20       Impact factor: 17.956
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.